🔎 Trials Near Me

ホーム › 急性二系統白血病

米国で参加者を募集している急性二系統白血病の臨床試験

米国全土の拠点で、急性二系統白血病に関する37件の研究が参加者を募集しています。

最も多くの研究がある都市

州別

最近更新された研究

公式研究テキスト（英語）

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

被験者募集中第1相
12歳〜78歳 · 全性別 · 2026/09/29更新 · NCT03802695

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

被験者募集中
18歳以上 · 全性別 · 2026/09/17更新 · NCT07094750

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT04375631

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

被験者募集中第1/2相
30 Days · 全性別 · 2026/09/16更新 · NCT04065399

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT03683433

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

被験者募集中第1/2相健康なボランティア歓迎
50歳以下 · 全性別 · 2026/09/01更新 · NCT05322850

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

被験者募集中第2相
1歳〜18歳 · 全性別 · 2026/08/10更新 · NCT06390319

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

被験者募集中第1相
1歳〜30歳 · 全性別 · 2026/08/03更新 · NCT06177067

Personalized NK Cell Therapy in CBT

被験者募集中第2相
15歳〜80歳 · 全性別 · 2026/07/30更新 · NCT02727803

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

被験者募集中第2相
6 Months – 65 Years · 全性別 · 2026/07/22更新 · NCT06013423

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

被験者募集中第2相
18歳以上 · 全性別 · 2026/07/20更新 · NCT07046078

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

被験者募集中第4相
1歳〜18歳 · 全性別 · 2026/07/14更新 · NCT06289673

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

被験者募集中第2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT07216443

Allo HSCT Using RIC and PTCy for Hematological Diseases

被験者募集中第2相
75歳以下 · 全性別 · 2026/07/06更新 · NCT05805605

Registry of Older Patients With Cancer

被験者募集中観察研究
65歳以上 · 全性別 · 2026/06/29更新 · NCT01137825

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/06/23更新 · NCT06551584

A Study of Revumenib and Mezigdomide in People With Leukemia

被験者募集中第1/2相
12歳以上 · 全性別 · 2026/06/22更新 · NCT07356154

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/06/22更新 · NCT03128034

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/06/22更新 · NCT03670966

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/12更新 · NCT04047641

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

被験者募集中第2相健康なボランティア歓迎
6 Months · 全性別 · 2026/05/29更新 · NCT04195633

ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。